![Glenmark Pharmaceuticals Glenmark Pharmaceuticals](https://bsmedia.business-standard.com/_media/bs/img/article/2019-08/14/full/1565801938-3166.jpg?im=Resize,width=640)
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Glenmark Pharmaceuticals | Pharma Companies | Heart Failure
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Glenmark Pharmaceuticals on Tuesday said it has launched sacubitril and valsartan combination tablets in India for treatment of heart failure.
The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.
Glenmark Pharmaceuticals EVP & Business Head India Formulations, Alok Malik said Sacu V is an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and to improve symptoms associated with heart failure with reduced ejection fraction (HFrEF).
The company said Sacu V must be taken twice daily under doctor's prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Tue, January 17 2023. 14:41 IST
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more
In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more
The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more
The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more